Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LEXINGTON, Mass., July 8, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on July 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 25,000 shares of Curis common stock to a new employee, with a grant date of July 1, 2024 (the "Q3 2024 Inducement Grant").
2024年7月8日，马萨诸塞州列克星敦市 /美通社/--Curis股份有限公司（纳斯达克：CRIS）是一家专注于开发可口服、小分子IRAK4抑制剂emavusertib（CA-4948）的生物技术公司。今天公告称，Curis独立薪酬委员会于2024年7月1日批准向新员工授予招致期权，以购买共计25,000股Curis普通股，授予日为2024年7月1日（"Q3 2024招致期权")。
The Q3 2024 Inducement Grant has an exercise price per share equal to the closing price of the Company's common stock on July 1, 2024. The stock option has a 10 year term and vests over four years, with 25% of the original number of shares underlying the award vesting on the first anniversary of the employee's date of hire and an additional 6.25% of the original number of shares underlying the award vesting on each successive three-month period thereafter, subject to the employee's continued service with the Company through the respective vesting dates. The stock option was granted as an inducement equity award outside of the Company's Fifth Amended and Restated 2010 Stock Incentive Plan and was made as an inducement material to the employee's acceptance of employment with the Company.
“Q3 2024招致期权”的行权价格等于公司普通股票于2024年7月1日的收盘价格。该期权有10年期限，分四年归属，即奖项原有股数的25%在员工入职后的第一周年纪念日归属，之后每三个月追加归属奖项原有股数的6.25%，前提是员工在各自的归属日继续在公司任职。该期权是作为公司的第五次修订和重订2010年股份激励计划外的招致权益奖项授予的，是员工接受公司就业所必需的招致物。
About Curis, Inc.
关于Curis公司 Curis是一家专注于开发可口服、小分子IRAK4抑制剂emavusertib的生物技术公司。目前，emavusertib正在接受第1/2期TakeAim淋巴瘤研究的测试，用于治疗复发/难治的原发性中枢神经系统淋巴瘤(PCNSL)，与BTk抑制剂ibrutinib联合使用，在复发/难治急性髓细胞白血病（AML）和复发/高风险骨髓增生异常综合征（hrMDS）携带FLT3基因突变或剪切因子突变的（U2AF1或SF3B2）患者中作为单药治疗，并作为与azacitidine和venetoclax联合前线治疗AML的组合疗法。Emavusertib已获美国食品和药物管理局的孤儿药品认证，用于治疗AML和MDS。Curis通过其与Aurigene的2015年合作，拥有emavusertib（CA-4948）的独家许可。Curis将其Erivedge的权利授权给罗氏集团成员Genentech，他们正在商业化Erivedge治疗晚期基底细胞癌。欲了解更多信息，请访问Curis公司的网站。
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge to Genentech, a member of the Roche Group, under which they are commercializing Erivedge for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at .
Curis是一家专注于开发可口服、小分子IRAK4抑制剂emavusertib的生物技术公司。Emavusertib目前正在接受测试，用于治疗复发/难治的原发性中枢神经系统淋巴瘤(PCNSL)，与BTk抑制剂ibrutinib联合使用，在复发/难治急性髓细胞白血病（AML）和复发/高风险骨髓增生异常综合征（hrMDS）携带FLT3基因突变或剪切因子突变的（U2AF1或SF3B2）患者中作为单药治疗，并作为与azacitidine和venetoclax联合前线治疗AML的组合疗法。Emavusertib已获美国食品和药物管理局的孤儿药品认证，用于治疗AML和MDS。Curis通过其与Aurigene的2015年合作，拥有emavusertib（CA-4948）的独家许可。Curis将其Erivedge的权利授权给罗氏集团成员Genentech，他们正在商业化Erivedge治疗晚期基底细胞癌。
SOURCE Curis, Inc.
来源：Curis，Inc。